Is Amylin a Two-Hit Wonder?

Having two drugs on the market and no profitability in the near future does not make for what I'd call a stellar earnings report. But investors in Amylin (Nasdaq: AMLN) are apparently looking ahead to future FDA approvals, which would help turn the company in the right direction. The stock is up more than 5% today after Amylin announced earnings Monday night.

Amylin brought in $197 million in revenues, including $167.3 million in product sales from its two diabetes-treating drugs and $29.6 million in payments from collaborators. The latter includes a $15 million milestone payment from marketing partner Eli Lilly (NYSE: LLY), primarily for the launch of Byetta in the European Union.

Amylin's other drug, Symlin, which it markets by itself, brought in $15.2 million, up 49% year over year. The company plans to further increase sales of this drug by making it available in a pen delivery system, which is more user-friendly than the vial form in which it's currently offered.

Sales of Byetta made up three-fourths of the total revenues for the quarter, and the $152.1 million in sales of the drug was a 54% better showing than last quarter. Yet even with the stellar increase, sales of the drug came in lower than expected because of competition with Merck's (NYSE: MRK) Januvia.

The increased sales also weren't enough to overcome expenses. Amylin lost $0.34 per share for the quarter, compared with a loss of $0.38 per share last year. The loss of $45 million, though, is nothing for a company with $1.1 billion in cash and short-term securities -- much of which comes from $559 million in convertible senior notes the company financed last month. Even with increased expenses from a new manufacturing plant, Amylin still has plenty of time to get more drugs out of its pipeline.

Much of the quarter's loss can be attributed to the $71.7 million Amylin spent on research and development, which was up more than 40% from last year. The company has two drugs in costly late-stage clinical trials: a long-acting version of exenatide, a diabetes-management drug that's in a phase 3 trial, and an anti-obesity drug, Pramlintide, which is in phase 2 trials. Results from both trials are scheduled to be released in the fourth quarter.

It's not a problem that companies with one or two drugs take a while to become profitable. After all, development costs for drugs in a pipeline can be tremendous. But for now, Amylin finds itself in the same place as developmental-stage drug companies: For the near future, it will live and die by the clinical trial results it releases.

Want to know the latest drug stock we've picked for the Fool's market-beating Rule Breakers newsletter service? You can take a look at all our recommendations, as well as get access to our message boards and exclusive content, with a 30-day free trial.

Eli Lilly is an Income Investor recommendation.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool's disclosure policy is rock-solid.